Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 3 long-term extension study of mirikizumab in ulcerative colitis
jRCT2080224003Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Started Aug 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224003.